Technology | August 29, 2013

Bayer Launches New Jetstream XC and SC Atherectomy Catheters

The catheters can be used to treat PAD and multiple lesion morphologies

August 29, 2013 — Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has cleared two new Jetstream atherectomy catheters. The SC (Single Cutter) atherectomy catheter is available in 1.6-mm and 1.85-mm cutting diameters.  The XC (eXpandable cutter) atherectomy catheter features both front cutting tip and expandable blade technology for use in larger vessels.  The XC is available in two cutting diameters: 2.1-mm blades down / 3.0-mm blades up and 2.4-mm blades down / 3.4-mm blades up.

Redesigned, integrated control pods feature:

  • Ergonomic design and smaller size (32 percent) for improved ease of use
  • New user interface to facilitate single or dual operator use 
  • Simplified guidewire management through improved wire GARD
  • Reduced storage space requirements and environmental impact through new control pod design and improved packaging

 

The Jetstream Atherectomy System is one of the most versatile debulking solutions for the treatment of peripheral artery disease (PAD).  The system catheters can be used to treat multiple lesion morphologies – from thrombus to the most challenging calcium deposits. Catheters are available in both SC and XC sizes to support treatment of vessels above and below the knee. The Jetstream System consists of a single-use catheter with control pod and a reusable, compact console that mounts to a standard IV stand. 

For more information: www.ri.bayer.com

Related Content

News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Overlay Init